Promising results for adjuvant pembrolizumab therapy in high-risk kidney cancer
Results from KEYNOTE-564 presented after the plenary session of ASCO 2021 show that adjuvant pembrolizumab therapy leads to a significant reduction in the risk of recurrence or death compared to placebo in patients with renal cell carcinoma.